头颈鳞癌标准分割时间羽状放疗安全性的体内评估:R-IDEAL 1/2a期首次人体可行性研究
该R-IDEAL 1/2a期研究在5例接受根治性放疗(70 Gy/35次)的头颈鳞癌患者中首次实施时间羽状放疗(TFRT),主要终点为CT模拟后15个工作日内开始放疗的可行性,4/5例达到;所有TFRT分次按正确顺序无误交付,5例中1例发生急性3级毒性。
要点
- TFRT计划可行性达标:5例中4例在CT模拟后15个工作日内开始放疗。
- 接受TFRT者CT模拟至放疗开始中位10个工作日(范围8–15),计划平均耗时6个工作日。
- 所有TFRT分次按正确顺序无误交付,5例中1例出现急性3级毒性。
核心结论
- 首次人体实施TFRT可行,可融入现代临床工作流程(R-IDEAL 1期)。
- 研究报告了急性毒性评估及与标准放疗计划的剂量学比较(R-IDEAL 2a期)。
研究设计与样本
- R-IDEAL 1/2a期首次人体可行性研究,入组接受根治性放疗(70 Gy/35次)的头颈鳞癌患者。
- 主要终点为TFRT计划可行性,定义为CT模拟后15个工作日内开始放疗;次要终点包括急性3–5级毒性估计。
- 研究达到5例的入组目标。
主要发现
- 5例中4例在CT模拟后15个工作日内生成TFRT计划并开始放疗,达到主要终点。
- 1例虽TFRT计划及时生成,但医生决定未行TFRT治疗。
- 接受TFRT者CT模拟至放疗开始中位10个工作日(范围8–15),放疗计划平均耗时6个工作日。
- 所有接受TFRT者每个子计划和每日分次均按正确顺序无误交付。
- 5例中1例发生急性3级毒性。
关键数值与推荐
- 处方剂量70 Gy分35次。
- 可行性阈值:CT模拟后15个工作日内开始放疗。
- 羽状保护的OAR包括口腔、双侧颌下腺、双侧腮腺、声门上区及咽后壁(OAR咽)。
- 每个TFRT子计划及复合计划均确保PTV处方剂量覆盖>95%。
临床怎么用
- TFRT可在现代放疗工作流程中实施,计划生成与交付顺序可控。
- 实施时需确保每个子计划及复合计划PTV覆盖>95%,并按正确顺序交付每日分次。
局限性
- 样本量仅5例,为首次人体可行性研究。
- 1例未按TFRT治疗,由医生决定。
- 急性毒性仅为估计,未设对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prior in silico simulations of studies of Temporally Feathered Radiation Therapy (TFRT) have demonstrated potential reduction in normal tissue toxicity. This R-IDEAL Stage 1/2A study seeks to demonstrate the first-in-human implementation of TFRT in treating patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Patients with HNSCC treated with definitive radiation therapy were eligible (70 Gy in 35 fractions) were eligible. The primary endpoint was feasibility of TFRT planning as defined by radiation start within 15 business days of CT simulation. Secondary endpoints included estimates of acute grade 3-5 toxicity. RESULTS: The study met its accrual goal of 5 patients. TFRT plans were generated in four of the five patients within 15 business days of CT simulation, therefore meeting the primary endpoint. One patient was not treated with TFRT at the physician's discretion, though the TFRT plan had been generated within sufficient time from the CT simulation. For patients who received TFRT, the median time from CT simulation to radiation start was 10 business days (range 8-15). The average time required for radiation planning was 6 business days. In all patients receiving TFRT, each subplan and every daily fraction was delivered in the correct sequence without error. The OARs feathered included: oral cavity, each submandibular gland, each parotid gland, supraglottis, and posterior pharyngeal wall (OAR pharynx). Prescription dose PTV coverage (>95%) was ensured in each TFRT subplan and the composite TFRT plan. One of five patients developed an acute grade 3 toxicity. CONCLUSIONS: This study demonstrates the first-in-human implementation of TFRT (R-IDEAL Stage 1), proving its feasibility in the modern clinical workflow. Additionally, assessments of acute toxicities and dosimetric comparisons to a standard radiotherapy plan were described (R-IDEAL Stage 2a).
引用
- Parsai S, Qiu RLJ, Qi P, et al. In vivo assessment of the safety of standard fractionation Temporally Feathered Radiation Therapy (TFRT) for head and neck squamous cell carcinoma: An R-IDEAL Stage 1/2a first-in-humans/feasibility demonstration of new technology implementation. Radiother Oncol. 2021. PMID: 34333086. doi:10.1016/j.radonc.2021.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。